{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:55:38Z","timestamp":1793498138374,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11886-023-01974-8","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:02:20Z","timestamp":1697533340000},"page":"1451-1460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7260-0388","authenticated-orcid":false,"suffix":"Jr.","given":"Robert Benson","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"1974_CR1","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Pacak K. New biology of pheochromocytoma and paraganglioma. Endocr Pract. 2022;28(12):1253-69. https:\/\/doi.org\/10.1016\/j.eprac.2022.09.003. A thorough review of the most recent advancements in PPGL biochemical, genetic, and therapeutic advancements.","DOI":"10.1016\/j.eprac.2022.09.003"},{"issue":"2","key":"1974_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc3648","volume":"14","author":"PLM Dahia","year":"2014","unstructured":"Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108\u201319. https:\/\/doi.org\/10.1038\/nrc3648.","journal-title":"Nat Rev Cancer."},{"issue":"11","key":"1974_CR3","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1210\/jcem.86.11.8034","volume":"86","author":"D Erickson","year":"2001","unstructured":"Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86(11):5210\u20136. https:\/\/doi.org\/10.1210\/jcem.86.11.8034.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"1974_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181\u201393. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001.","journal-title":"Cancer Cell."},{"issue":"4","key":"1974_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41574-020-0324-1","volume":"16","author":"PLM Dahia","year":"2020","unstructured":"Dahia PLM, Toledo RA. Recognizing hypoxia in phaeochromocytomas and paragangliomas. Nat Rev Endocr. 2020;16(4):191\u20132. https:\/\/doi.org\/10.1038\/s41574-020-0324-1.","journal-title":"Nat Rev Endocr."},{"issue":"2","key":"1974_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ppedcard.2010.06.011","volume":"29","author":"PS McQuillen","year":"2010","unstructured":"McQuillen PS, Goff DA, Licht DJ. Effects of congenital heart disease on brain development. Prog Pediatr Cardiol. 2010;29(2):79\u201385. https:\/\/doi.org\/10.1016\/j.ppedcard.2010.06.011.","journal-title":"Prog Pediatr Cardiol."},{"issue":"22","key":"1974_CR7","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1161\/circulationaha.110.946343","volume":"122","author":"P Moons","year":"2010","unstructured":"Moons P, Bovijn L, Budts W, Belmans A, Gewillig M. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium. Circulation. 2010;122(22):2264\u201372. https:\/\/doi.org\/10.1161\/circulationaha.110.946343.","journal-title":"Circulation."},{"issue":"9","key":"1974_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/circulationaha.113.008396","volume":"130","author":"AJ Marelli","year":"2014","unstructured":"Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749\u201356. https:\/\/doi.org\/10.1161\/circulationaha.113.008396.","journal-title":"Circulation."},{"key":"1974_CR9","doi-asserted-by":"publisher","unstructured":"\u2022\u00a0Ogasawara T, Fujii Y, Kakiuchi N, Shiozawa Y, Sakamoto R, Ogawa Y, Ootani K, Ito E, Tanaka T, Watanabe K, Yoshida Y. Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease.\u00a0J Clin Endocrinol Metab.\u00a02022;107(9):2545-55.\u00a0https:\/\/doi.org\/10.1210\/clinem\/dgac362. This study of CCHD-PPGL patients found 15\/16 samples carried somaticmutation for EPAS1, suggesting that selective pressure of hypoxia can lead to this mutation.","DOI":"10.1210\/clinem\/dgac362"},{"key":"1974_CR10","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Opotowsky AR, Moko LE, Ginns J, Rosenbaum M, Greutmann M, Aboulhosn J, et al. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease.\u00a0J Clin Endocrinol Metab. 2015;100(4):1325-34. https:\/\/doi.org\/10.1210\/jc.2014-3863. This study performed clinical, biochemical, and genetic analysis of a cohort of 18 CCHD-PPGL patients and identified noradrenergic, rather than adrenergic, biochemical predominance.","DOI":"10.1210\/jc.2014-3863"},{"key":"1974_CR11","doi-asserted-by":"publisher","unstructured":"Ponz de Antonio I, Ruiz Cantador J, Gonz\u00e1lez Garc\u00eda AE, Oliver Ruiz JM, S\u00e1nchez-Recalde \u00c1, L\u00f3pez-Send\u00f3n JL. Prevalence of neuroendocrine tumors in patients with cyanotic congenital heart disease. Rev Esp Cardiol (Engl Ed). 2017;70(8):673-5. https:\/\/doi.org\/10.1016\/j.rec.2016.09.036.","DOI":"10.1016\/j.rec.2016.09.036"},{"key":"1974_CR12","doi-asserted-by":"publisher","unstructured":"\u2022 Dahia PLM, Clifton-Bligh R, Gimenez-Roqueplo A-P, Robledo M, Jimenez C. Hereditary endocrine tumours: current state-of-the-art and research opportunities: metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop. Endocrine-Related Cancer. 2020;27(8):T41-T52. https:\/\/doi.org\/10.1530\/erc-19-0435. An excellent review of the current genetic and potential therapeutic targets for PPGL.","DOI":"10.1530\/erc-19-0435"},{"issue":"12","key":"1974_CR13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1001\/jama.2016.12386","volume":"316","author":"WG Kaelin Jr","year":"2016","unstructured":"Kaelin WG Jr, Ratcliffe PJ, Semenza GL. Pathways for oxygen regulation and homeostasis: the 2016 Albert Lasker basic medical research award. Jama. 2016;316(12):1252\u20133. https:\/\/doi.org\/10.1001\/jama.2016.12386.","journal-title":"Jama."},{"issue":"2","key":"1974_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.yexcr.2004.10.003","volume":"303","author":"H Nilsson","year":"2005","unstructured":"Nilsson H, J\u00f6gi A, Beckman S, Harris AL, Poellinger L, P\u00e5hlman S. HIF-2\u03b1 expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp Cell Res. 2005;303(2):447\u201356. https:\/\/doi.org\/10.1016\/j.yexcr.2004.10.003.","journal-title":"Exp Cell Res."},{"issue":"2","key":"1974_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1158\/0008-5472.Can-21-3780","volume":"82","author":"LC Kim","year":"2022","unstructured":"Kim LC, Simon MC. Hypoxia-inducible factors in cancer. Cancer Res. 2022;82(2):195\u20136. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-3780.","journal-title":"Cancer Res."},{"issue":"5516","key":"1974_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","volume":"292","author":"M Ivan","year":"2001","unstructured":"Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464\u20138. https:\/\/doi.org\/10.1126\/science.1059817.","journal-title":"Science."},{"issue":"5112","key":"1974_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317\u201320. https:\/\/doi.org\/10.1126\/science.8493574.","journal-title":"Science."},{"issue":"20","key":"1974_CR18","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","volume":"20","author":"N Burnichon","year":"2011","unstructured":"Burnichon N, Vescovo L, Amar L, Lib\u00e9 R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20(20):3974\u201385. https:\/\/doi.org\/10.1093\/hmg\/ddr324.","journal-title":"Hum Mol Genet."},{"issue":"12","key":"1974_CR19","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1210\/me.2010-0256","volume":"24","author":"E L\u00f3pez-Jim\u00e9nez","year":"2010","unstructured":"L\u00f3pez-Jim\u00e9nez E, G\u00f3mez-L\u00f3pez G, Leandro-Garc\u00eda LJ, Mu\u00f1oz I, Schiavi F, Montero-Conde C, et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24(12):2382\u201391. https:\/\/doi.org\/10.1210\/me.2010-0256.","journal-title":"Mol Endocrinol."},{"issue":"4","key":"1974_CR20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1677\/erc.1.00838","volume":"11","author":"G Eisenhofer","year":"2004","unstructured":"Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer. 2004;11(4):897\u2013911. https:\/\/doi.org\/10.1677\/erc.1.00838.","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"1974_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","volume":"1","author":"PL Dahia","year":"2005","unstructured":"Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005;1(1):72\u201380. https:\/\/doi.org\/10.1371\/journal.pgen.0010008.","journal-title":"PLoS Genet."},{"issue":"1","key":"1974_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","volume":"93","author":"C Yang","year":"2015","unstructured":"Yang C, Zhuang Z, Fliedner SM, Shankavaram U, Sun MG, Bullova P, et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia. J Mol Med (Berl). 2015;93(1):93\u2013104. https:\/\/doi.org\/10.1007\/s00109-014-1205-7.","journal-title":"J Mol Med (Berl)."},{"issue":"12","key":"1974_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1530\/erc-21-0211","volume":"28","author":"L Eckardt","year":"2021","unstructured":"Eckardt L, Prange-Barczynska M, Hodson EJ, Fielding JW, Cheng X, Lima J, et al. Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma. Endocr Relat Cancer. 2021;28(12):757\u201372. https:\/\/doi.org\/10.1530\/erc-21-0211.","journal-title":"Endocr Relat Cancer."},{"issue":"9","key":"1974_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/onc.2015.172","volume":"35","author":"LJ Castro-Vega","year":"2016","unstructured":"Castro-Vega LJ, Lepoutre-Lussey C, Gimenez-Roqueplo AP, Favier J. Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene. 2016;35(9):1080\u20139. https:\/\/doi.org\/10.1038\/onc.2015.172.","journal-title":"Oncogene."},{"issue":"1","key":"1974_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77\u201385. https:\/\/doi.org\/10.1016\/j.ccr.2004.11.022.","journal-title":"Cancer Cell."},{"issue":"24","key":"1974_CR26","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1093\/hmg\/ddm275","volume":"16","author":"EH Smith","year":"2007","unstructured":"Smith EH, Janknecht R, Maher LJ 3rd. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet. 2007;16(24):3136\u201348. https:\/\/doi.org\/10.1093\/hmg\/ddm275.","journal-title":"Hum Mol Genet."},{"issue":"12","key":"1974_CR27","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41568-020-00303-3","volume":"20","author":"JA Losman","year":"2020","unstructured":"Losman JA, Koivunen P, Kaelin WG Jr. 2-Oxoglutarate-dependent dioxygenases in cancer. Nat Rev Cancer. 2020;20(12):710\u201326. https:\/\/doi.org\/10.1038\/s41568-020-00303-3.","journal-title":"Nat Rev Cancer."},{"issue":"10","key":"1974_CR28","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1210\/clinem\/dgac474","volume":"107","author":"C Lamy","year":"2022","unstructured":"Lamy C, Tissot H, Faron M, Baudin E, Lamartina L, Pradon C, et al. Succinate: a serum biomarker of SDHB-mutated paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2022;107(10):2801\u201310. https:\/\/doi.org\/10.1210\/clinem\/dgac474.","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"1974_CR29","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1056\/NEJMoa1205119","volume":"367","author":"Z Zhuang","year":"2012","unstructured":"Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367(10):922\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1205119.","journal-title":"N Engl J Med."},{"key":"1974_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/ERC-13-0101","volume":"20","author":"R Toledo","year":"2013","unstructured":"Toledo R, Qin Y, Srikantan S, Morales N, Li Q, Deng Y, et al. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2013;20:349\u201359.","journal-title":"Endocr Relat Cancer."},{"issue":"11","key":"1974_CR31","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","volume":"22","author":"I Comino-M\u00e9ndez","year":"2013","unstructured":"Comino-M\u00e9ndez I, de Cubas AA, Bernal C, \u00c1lvarez-Escol\u00e1 C, S\u00e1nchez-Malo C, Ram\u00edrez-Tortosa CL, et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet. 2013;22(11):2169\u201376. https:\/\/doi.org\/10.1093\/hmg\/ddt069.","journal-title":"Hum Mol Genet."},{"issue":"3","key":"1974_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/erc-13-0384","volume":"21","author":"J Welander","year":"2014","unstructured":"Welander J, Andreasson A, Brauckhoff M, B\u00e4ckdahl M, Larsson C, Gimm O, et al. Frequent EPAS1\/HIF2\u03b1 exons 9 and 12 mutations in non-familial pheochromocytoma. Endocr Relat Cancer. 2014;21(3):495\u2013504. https:\/\/doi.org\/10.1530\/erc-13-0384.","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"1974_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/s0046-8177(76)80052-4","volume":"7","author":"J Arias-Stella","year":"1976","unstructured":"Arias-Stella J, Valcarcel J. Chief cell hyperplasia in the human carotid body at high altitudes; physiologic and pathologic significance. Hum Pathol. 1976;7(4):361\u201373. https:\/\/doi.org\/10.1016\/s0046-8177(76)80052-4.","journal-title":"Hum Pathol."},{"issue":"3","key":"1974_CR34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/1097-0142(19860201)57:3<672::aid-cncr2820570346>3.0.co;2-c","volume":"57","author":"H Rodriguez-Cuevas","year":"1986","unstructured":"Rodriguez-Cuevas H, Lau I, Rodriguez HP. High-altitude paragangliomas diagnostic and therapeutic considerations. Cancer. 1986;57(3):672\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19860201)57:3%3c672::aid-cncr2820570346%3e3.0.co;2-c.","journal-title":"Cancer."},{"issue":"5","key":"1974_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/15385744231154089","volume":"57","author":"M Gonzalez-Urquijo","year":"2023","unstructured":"Gonzalez-Urquijo M, Hinojosa-Gonzalez DE, Fabiani MA, Gonz\u00e1lez-Gonz\u00e1lez M, Cardenas-Figueroa EG, Rosero-Aguirre VA, et al. High altitude carotid body tumors growth during active surveillance. Vasc Endovascular Surg. 2023;57(5):451\u20135. https:\/\/doi.org\/10.1177\/15385744231154089.","journal-title":"Vasc Endovascular Surg."},{"issue":"2","key":"1974_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0046-8177(73)80012-7","volume":"4","author":"MJ Saldana","year":"1973","unstructured":"Saldana MJ, Salem LE, Travezan R. High altitude hypoxia and chemodectomas. Human Pathol. 1973;4(2):251\u201363. https:\/\/doi.org\/10.1016\/S0046-8177(73)80012-7.","journal-title":"Human Pathol."},{"issue":"13","key":"1974_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1056\/NEJMc1716652","volume":"378","author":"A Vaidya","year":"2018","unstructured":"Vaidya A, Flores SK, Cheng Z-M, Nicolas M, Deng Y, Opotowsky AR, et al. EPAS1 mutations and paragangliomas in cyanotic congenital heart disease. N Engl J Med. 2018;378(13):1259\u201361. https:\/\/doi.org\/10.1056\/NEJMc1716652.","journal-title":"N Engl J Med."},{"key":"1974_CR38","doi-asserted-by":"publisher","unstructured":"\u2022 Zhao B, Zhou Y, Zhao Y, Zhao Y, Wu X, Bi Y, et al. Co-occurrence of pheochromocytoma-paraganglioma and cyanotic congenital heart disease: a case report and literature review. Front Endocrinol (Lausanne). 2018;9:165. https:\/\/doi.org\/10.3389\/fendo.2018.00165. A collection of 47 case reports of CCHD-PPGL, this study provides the largest published collection of CCHD-PPGL.","DOI":"10.3389\/fendo.2018.00165"},{"issue":"3","key":"1974_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","volume":"57","author":"G Eisenhofer","year":"2011","unstructured":"Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57(3):411\u201320. https:\/\/doi.org\/10.1373\/clinchem.2010.153320.","journal-title":"Clin Chem."},{"issue":"5","key":"1974_CR40","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1210\/jcem.86.5.7496","volume":"86","author":"G Eisenhofer","year":"2001","unstructured":"Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab. 2001;86(5):1999\u20132008. https:\/\/doi.org\/10.1210\/jcem.86.5.7496.","journal-title":"J Clin Endocrinol Metab."},{"issue":"13","key":"1974_CR41","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1200\/jco.2012.47.1912","volume":"31","author":"K Pacak","year":"2013","unstructured":"Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013;31(13):1690\u20138. https:\/\/doi.org\/10.1200\/jco.2012.47.1912.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1974_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101354","volume":"34","author":"S Jasim","year":"2020","unstructured":"Jasim S, Jimenez C. Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract Res Clin Endocrinol Metab. 2020;34(2): 101354. https:\/\/doi.org\/10.1016\/j.beem.2019.101354.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"11","key":"1974_CR43","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas. Cancer. 2012;118(11):2804\u201312. https:\/\/doi.org\/10.1002\/cncr.26577.","journal-title":"Cancer."},{"issue":"2","key":"1974_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/157488408784293705","volume":"3","author":"MJ Roodhart","year":"2008","unstructured":"Roodhart MJ, Langenberg HM, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway. Curr Clin Pharmacol. 2008;3(2):132\u201343. https:\/\/doi.org\/10.2174\/157488408784293705.","journal-title":"Curr Clin Pharmacol."},{"issue":"2","key":"1974_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/cancers11020195","volume":"11","author":"J Kohlenberg","year":"2019","unstructured":"Kohlenberg J, Welch B, Hamidi O, Callstrom M, Morris J, Sprung J, et al. Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma. Cancers. 2019;11(2):195.","journal-title":"Cancers."},{"issue":"3","key":"1974_CR46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12020-017-1515-y","volume":"59","author":"G Gravel","year":"2018","unstructured":"Gravel G, Leboulleux S, Tselikas L, Fassio F, Berraf M, Berdelou A, et al. Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma. Endocrine. 2018;59(3):547\u201354. https:\/\/doi.org\/10.1007\/s12020-017-1515-y.","journal-title":"Endocrine."},{"issue":"5","key":"1974_CR47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60(5):623\u201330. https:\/\/doi.org\/10.2967\/jnumed.118.217463.","journal-title":"J Nucl Med."},{"issue":"22","key":"1974_CR48","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.Ccr-22-1054","volume":"28","author":"J Fallah","year":"2022","unstructured":"Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. FDA approval summary: belzutifan for von Hippel-Lindau disease-associated tumors. Clin Cancer Res. 2022;28(22):4843\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1054.","journal-title":"Clin Cancer Res."},{"issue":"22","key":"1974_CR49","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2103425.","journal-title":"N Engl J Med."},{"issue":"22","key":"1974_CR50","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","volume":"385","author":"J Kamihara","year":"2021","unstructured":"Kamihara J, Hamilton KV, Pollard JA, Clinton CM, Madden JA, Lin J, et al. Belzutifan, a potent HIF2\u03b1 inhibitor, in the Pacak-Zhuang syndrome. N Engl J Med. 2021;385(22):2059\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2110051.","journal-title":"N Engl J Med."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-023-01974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-023-01974-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-023-01974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T03:19:24Z","timestamp":1701141564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-023-01974-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1974"],"URL":"https:\/\/doi.org\/10.1007\/s11886-023-01974-8","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"28 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RBJ reports no financial disclosures. DLC reports no financial disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}